• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

三阴性乳腺癌治疗药物研发的最新进展。

Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment.

机构信息

Department of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics, Catholic University of the Sacred Heart, Largo Francesco Vito 1, 00168 Rome, Italy.

Department of Neurosciences, Section of Human Anatomy, Catholic University of the Sacred Heart, Largo Francesco Vito 1, 00168 Rome, Italy.

出版信息

Molecules. 2023 Nov 9;28(22):7513. doi: 10.3390/molecules28227513.

DOI:10.3390/molecules28227513
PMID:38005235
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10672974/
Abstract

Triple-negative breast cancer (TNBC) is one of the most heterogeneous and aggressive breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very difficult to treat due to the lack of an effective targeted therapy. However, recent advances in the molecular characterization of TNBC are encouraging the development of novel drugs and therapeutic combinations for its therapeutic management. In the present review, we will provide an overview of the currently available standard therapies and new emerging therapeutic strategies against TNBC, highlighting the promises that newly developed small molecules, repositioned drugs, and combination therapies have of improving treatment efficacy against these tumors.

摘要

三阴性乳腺癌（TNBC）是一种最具异质性和侵袭性的乳腺癌亚型，复发后死亡风险很高。迄今为止，由于缺乏有效的靶向治疗，TNBC 非常难以治疗。然而，TNBC 的分子特征研究的最新进展令人鼓舞，为其治疗管理开发了新的药物和治疗组合。在本综述中，我们将概述目前针对 TNBC 的标准治疗方法和新出现的治疗策略，重点介绍新开发的小分子、重新定位的药物和联合治疗在提高这些肿瘤治疗效果方面的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/7554013a61b4/molecules-28-07513-g021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/b5cb09bf7411/molecules-28-07513-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/301e146d7be4/molecules-28-07513-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/c53b9b62696b/molecules-28-07513-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/f0dcf7181eb1/molecules-28-07513-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/b93fb41e1d72/molecules-28-07513-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/8cb3bc3e7975/molecules-28-07513-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/e30d8240d172/molecules-28-07513-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/7a89d6eadf79/molecules-28-07513-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/94d8573d836f/molecules-28-07513-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/e3e5d9403602/molecules-28-07513-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/8d4b8f7c6548/molecules-28-07513-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/48e3496296c5/molecules-28-07513-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/6f24416b6b4a/molecules-28-07513-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/7ce9f281f0b4/molecules-28-07513-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/f3db6945a02f/molecules-28-07513-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/340cfd21e269/molecules-28-07513-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/d19604598f6a/molecules-28-07513-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/3e02c65fc0d2/molecules-28-07513-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/ace6570a0223/molecules-28-07513-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/a83e95cbf55f/molecules-28-07513-g020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/7554013a61b4/molecules-28-07513-g021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/b5cb09bf7411/molecules-28-07513-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/301e146d7be4/molecules-28-07513-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/c53b9b62696b/molecules-28-07513-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/f0dcf7181eb1/molecules-28-07513-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/b93fb41e1d72/molecules-28-07513-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/8cb3bc3e7975/molecules-28-07513-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/e30d8240d172/molecules-28-07513-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/7a89d6eadf79/molecules-28-07513-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/94d8573d836f/molecules-28-07513-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/e3e5d9403602/molecules-28-07513-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/8d4b8f7c6548/molecules-28-07513-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/48e3496296c5/molecules-28-07513-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/6f24416b6b4a/molecules-28-07513-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/7ce9f281f0b4/molecules-28-07513-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/f3db6945a02f/molecules-28-07513-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/340cfd21e269/molecules-28-07513-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/d19604598f6a/molecules-28-07513-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/3e02c65fc0d2/molecules-28-07513-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/ace6570a0223/molecules-28-07513-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/a83e95cbf55f/molecules-28-07513-g020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5aa6/10672974/7554013a61b4/molecules-28-07513-g021.jpg

相似文献

1
Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment.三阴性乳腺癌治疗药物研发的最新进展。
Molecules. 2023 Nov 9;28(22):7513. doi: 10.3390/molecules28227513.
2
Targeted Therapies for Triple-Negative Breast Cancer.三阴性乳腺癌的靶向治疗。
Curr Treat Options Oncol. 2019 Nov 21;20(11):82. doi: 10.1007/s11864-019-0682-x.
3
The treatment landscape of triple-negative breast cancer.三阴性乳腺癌的治疗现状。
Med Oncol. 2024 Aug 29;41(10):236. doi: 10.1007/s12032-024-02456-9.
4
Biology and Management of Patients With Triple-Negative Breast Cancer.三阴性乳腺癌患者的生物学特性与管理
Oncologist. 2016 Sep;21(9):1050-62. doi: 10.1634/theoncologist.2016-0067. Epub 2016 Jul 11.
5
Advances in small-molecule drug discovery for triple-negative breast cancer.三阴性乳腺癌小分子药物研发进展
Future Med Chem. 2015;7(15):2019-39. doi: 10.4155/fmc.15.129. Epub 2015 Oct 23.
6
Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.激酶抑制剂在三阴性乳腺癌精准治疗中的应用：靶向这种异质性疾病的进展、挑战和新视角。
Cancer Lett. 2022 Oct 28;547:215775. doi: 10.1016/j.canlet.2022.215775. Epub 2022 Jun 3.
7
Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer.目前和新型联合治疗转移性三阴性乳腺癌。
Curr Oncol. 2022 Jul 7;29(7):4748-4767. doi: 10.3390/curroncol29070377.
8
Emerging Therapeutics for Patients with Triple-Negative Breast Cancer.三阴性乳腺癌的新兴治疗方法。
Curr Oncol Rep. 2021 Mar 24;23(5):57. doi: 10.1007/s11912-021-01038-6.
9
Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.三阴性乳腺癌的免疫治疗：现存挑战与振奋前景。
Drug Resist Updat. 2017 May;32:1-15. doi: 10.1016/j.drup.2017.07.002. Epub 2017 Aug 19.
10
TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy.TROPION-Breast03：一项关于datopotamab deruxtecan联合或不联合度伐利尤单抗用于新辅助治疗后手术切除时有三阴性乳腺癌和残留浸润性疾病患者的随机III期全球试验。
Ther Adv Med Oncol. 2024 Apr 29;16:17588359241248336. doi: 10.1177/17588359241248336. eCollection 2024.

引用本文的文献

1
Liposomal Formulations for Efficient Delivery of a Novel, Highly Potent Pyrimidine-Based Anticancer Drug.用于高效递送新型强效嘧啶类抗癌药物的脂质体制剂
Pharmaceuticals (Basel). 2025 Aug 15;18(8):1210. doi: 10.3390/ph18081210.
2
Comprehensive genomic profiling of Taiwanese triple-negative breast cancer samples with medium- and large-sized sequencing panels: A comparative study implicating treatment allocations.使用中型和大型测序面板对台湾三阴性乳腺癌样本进行综合基因组分析：一项涉及治疗分配的比较研究。
Biomed Rep. 2025 Aug 5;23(4):162. doi: 10.3892/br.2025.2040. eCollection 2025 Oct.
3
IBCar: Potent Orally Bioavailable Methyl -[5-(3'-Iodobenzoyl)-1-Benzimidazol-2-yl]Carbamate for Breast Cancer Therapy.

本文引用的文献

1
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.在 CDK7 抑制剂 samuraciclib 的 I 期研究中，晚期乳腺癌患者的剂量递增和扩展队列。
Nat Commun. 2023 Jul 24;14(1):4444. doi: 10.1038/s41467-023-40061-y.
2
Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer.发现一种新型 CDK12 和 PARP1 的双重靶向抑制剂，可诱导三阴性乳腺癌的合成致死作用。
Eur J Med Chem. 2023 Nov 5;259:115648. doi: 10.1016/j.ejmech.2023.115648. Epub 2023 Jul 16.
3
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
IBCar：用于乳腺癌治疗的强效口服生物可利用的甲基-[5-(3'-碘苯甲酰基)-1-苯并咪唑-2-基]氨基甲酸酯
Cancers (Basel). 2025 Jul 30;17(15):2526. doi: 10.3390/cancers17152526.
4
A genotype-to-drug diffusion model for generation of tailored anti-cancer small molecules.一种用于生成定制抗癌小分子的基因型到药物扩散模型。
Nat Commun. 2025 Jul 1;16(1):5628. doi: 10.1038/s41467-025-60763-9.
5
Epithelial-mesenchymal plasticity in cancer: signaling pathways and therapeutic targets.癌症中的上皮-间质可塑性：信号通路与治疗靶点。
MedComm (2020). 2024 Aug 1;5(8):e659. doi: 10.1002/mco2.659. eCollection 2024 Aug.
6
MALSU1-mediated regulation of mitochondrial function governs proliferation and doxorubicin resistance in triple-negative breast cancer cells.MALSU1介导的线粒体功能调节控制三阴性乳腺癌细胞的增殖和阿霉素耐药性。
Mol Cell Biochem. 2025 Feb;480(2):1197-1207. doi: 10.1007/s11010-024-05053-6. Epub 2024 Jun 19.
7
FEN1 Inhibition as a Potential Novel Targeted Therapy against Breast Cancer and the Prognostic Relevance of FEN1.FEN1 抑制作为一种针对乳腺癌的潜在新型靶向治疗方法及 FEN1 的预后相关性。
Int J Mol Sci. 2024 Feb 9;25(4):2110. doi: 10.3390/ijms25042110.
一项评估新型 Wee1 抑制剂adavosertib（AZD1775）单药治疗晚期实体瘤患者的安全性、耐受性和疗效的 Ib 期研究。
Target Oncol. 2023 Jul;18(4):517-530. doi: 10.1007/s11523-023-00965-7. Epub 2023 Jun 6.
4
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors.GSK3368715 是一种 I 型 PRMT 抑制剂的 1 期临床研究，评估其在晚期实体瘤患者中的安全性、耐受性、药代动力学和初步疗效。
Br J Cancer. 2023 Aug;129(2):309-317. doi: 10.1038/s41416-023-02276-0. Epub 2023 May 26.
5
Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.双重抑制 CDK12 和 CDK13 揭示了源自患者的卵巢癌类器官中的可靶向弱点。
J Exp Clin Cancer Res. 2023 May 18;42(1):126. doi: 10.1186/s13046-023-02682-5.
6
Disruption of CDK7 signaling leads to catastrophic chromosomal instability coupled with a loss of condensin-mediated chromatin compaction.CDK7 信号的破坏导致灾难性的染色体不稳定，同时伴有凝聚素介导的染色质紧缩的丧失。
J Biol Chem. 2023 Jul;299(7):104834. doi: 10.1016/j.jbc.2023.104834. Epub 2023 May 17.
7
CDK12/13 promote splicing of proximal introns by enhancing the interaction between RNA polymerase II and the splicing factor SF3B1.CDK12/13 通过增强 RNA 聚合酶 II 与剪接因子 SF3B1 之间的相互作用来促进近端内含子的剪接。
Nucleic Acids Res. 2023 Jun 23;51(11):5512-5526. doi: 10.1093/nar/gkad258.
8
Sacituzumab Govitecan as a Second-Line Treatment in Relapsed/Refractory Metastatic Triple-Negative Breast Cancer Patients: A Systematic Review and Meta-analysis.戈沙妥珠单抗作为复发/难治性转移性三阴性乳腺癌患者的二线治疗：一项系统评价和荟萃分析
Ann Pharmacother. 2024 Jan;58(1):44-53. doi: 10.1177/10600280231164110. Epub 2023 Apr 6.
9
Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial.基于亚型的平台指导了对经大量预处理的转移性三阴性乳腺癌的精准医学治疗：FUTURE 二期伞式临床试验。
Cell Res. 2023 May;33(5):389-402. doi: 10.1038/s41422-023-00795-2. Epub 2023 Mar 27.
10
Paraoxonase-2 is upregulated in triple negative breast cancer and contributes to tumor progression and chemoresistance.对氧磷酶 2 在三阴性乳腺癌中上调，并促进肿瘤进展和化疗耐药性。
Hum Cell. 2023 May;36(3):1108-1119. doi: 10.1007/s13577-023-00892-9. Epub 2023 Mar 10.